- Home
- ITOC vs BIAF Comparison
ITOC vs BIAF Comparison
Compare ITOC & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ITOC | BIAF |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | China | United States |
| Employees | 7 | 57 |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 4.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ITOC | BIAF |
|---|---|---|
| Price | $0.33 | $0.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 353.8K |
| Earning Date | 03-20-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $20.95 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.23 |
| 52 Week High | $1.15 | $13.50 |
Technical Indicators
Market Signals| Indicator | ITOC | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 24.46 |
| Support Level | $0.29 | N/A |
| Resistance Level | $0.41 | $1.45 |
| Average True Range (ATR) | 0.12 | 0.21 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 4.01 | 2.71 |
Price Performance
Historical ComparisonAbout ITOC iTonic Holdings Ltd Class A Ordinary Shares
iTonic Holdings Ltd through its subsidiary, focuses on healthcare solutions for brachytherapy, a targeted radiation therapy used in cancer treatment. Its product, Beijing Feitian's Treatment Planning System, helps ensure safe and effective brachytherapy using radioactive sources inside the patient to kill cancer cells and shrink tumors. Its product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device, etc.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.